07.11.23
Booth S0347
In a study on people who had at least four common colds in the preceding year, supplementing with a beta-glucan ingredient branded as PureMune by AIDP’s partner Immudyne resulted in increased production of immune cells. Namely, over a 90-day period in which participants took a daily dose of 30 mg of beta-glucan daily, significant increases were observed in levels of interferon-gamma (IFNy), interleukin-2 (IL-2), and the IFNy/interleukin-4 (IL-4) ratio.
Together, this contributed to reduced incidence and duration of symptomatic episodes compared to the same winter period the year before. The study was conducted among healthy participants who had at least four common colds over the preceding 12 months, and lasted 90 days.
Beta-glucan has been found in previous research to stimulate the immune system, promoting the activation of certain immune cells such as macrophages and neutrophils. Puremune is a patented, fast acting, low dose formulation of beta-glucan compared to other forms.
Conventional beta-glucan ingredients, on average, need six to 12 days to produce a clinically relevant response in only one immune pathway, usually at a dose of 250 mg or more. PureMune has been evidence to support onset of action within three hours, according to AIDP, and supports activation of dectin-1 receptors, toll-like receptors, and complement receptor 3, at a daily efficacious dose of 30 mg.
“Our research has shown best-in-class PureMune to be a very fast-acting and high-performing betaglucan ingredient for immune support," said Mark McLaughlin, chief executive officer of Immudyne Nutritional. “PureMune’s low dosage offers many benefits when developing immune health products as companies can now blend in other science-based immune ingredients such as probiotics, vitamin C or elderberry to create optimal immune formulations using different delivery systems.”
“Adding new research to the Puremune portfolio provides an added advantage for our customers and consumers,” said Mark Thurston, president of AIDP.
PureMune beta-glucan is standardized to specific beta-glucan content, and utilizes Eurofins’ carbon-12 high-resolution nuclear magnetic resonance testing to validate purity, authenticity, and freedom from common allergens.
In a study on people who had at least four common colds in the preceding year, supplementing with a beta-glucan ingredient branded as PureMune by AIDP’s partner Immudyne resulted in increased production of immune cells. Namely, over a 90-day period in which participants took a daily dose of 30 mg of beta-glucan daily, significant increases were observed in levels of interferon-gamma (IFNy), interleukin-2 (IL-2), and the IFNy/interleukin-4 (IL-4) ratio.
Together, this contributed to reduced incidence and duration of symptomatic episodes compared to the same winter period the year before. The study was conducted among healthy participants who had at least four common colds over the preceding 12 months, and lasted 90 days.
Beta-glucan has been found in previous research to stimulate the immune system, promoting the activation of certain immune cells such as macrophages and neutrophils. Puremune is a patented, fast acting, low dose formulation of beta-glucan compared to other forms.
Conventional beta-glucan ingredients, on average, need six to 12 days to produce a clinically relevant response in only one immune pathway, usually at a dose of 250 mg or more. PureMune has been evidence to support onset of action within three hours, according to AIDP, and supports activation of dectin-1 receptors, toll-like receptors, and complement receptor 3, at a daily efficacious dose of 30 mg.
“Our research has shown best-in-class PureMune to be a very fast-acting and high-performing betaglucan ingredient for immune support," said Mark McLaughlin, chief executive officer of Immudyne Nutritional. “PureMune’s low dosage offers many benefits when developing immune health products as companies can now blend in other science-based immune ingredients such as probiotics, vitamin C or elderberry to create optimal immune formulations using different delivery systems.”
“Adding new research to the Puremune portfolio provides an added advantage for our customers and consumers,” said Mark Thurston, president of AIDP.
PureMune beta-glucan is standardized to specific beta-glucan content, and utilizes Eurofins’ carbon-12 high-resolution nuclear magnetic resonance testing to validate purity, authenticity, and freedom from common allergens.
